Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists

US6699860B2 · kind B2 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Gaetan Ladouceur · Guilford, US
• William Bullock · Easton, US
• Steven R. Magnuson · South San Francisco, US
• Stephen O'Connor · Wilmette, US
• Roger Smith · Madison, US
• Quanrong Shen · Indianapolis, US
• Qingjie Liu · Newtown, US
• Ning Su · Hamden, US
• Emil Velthuisen · Irvine, US
• Ann-Marie Campbell · Monroe, US
• Paul P. Ehrlich · Libertyville, US

Key dates

• Filing date: Dec 7, 2001
• Grant date: Mar 2, 2004
• Expiry date: Dec 7, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.